Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors

Show simple item record

dc.contributor.author Suarez-Almazor, Maria
dc.contributor.author Pundole, Xerxes
dc.contributor.author Abdel-Wahab, Noha
dc.contributor.author Johnson, Douglas
dc.contributor.author Gupta, Dipti
dc.contributor.author Glezerman, Ilya
dc.contributor.author Cooksley, Tim
dc.contributor.author Anderson, Ronald
dc.contributor.author Blidner, Ada G.
dc.contributor.author Choi, Jennifer
dc.contributor.author Dougan, Michael
dc.contributor.author Ginex, Pamela
dc.contributor.author Girotra, Monica
dc.contributor.author Shannon, Vickie R.
dc.contributor.author Rapoport, Bernardo Leon
dc.date.accessioned 2020-10-26T11:51:41Z
dc.date.issued 2020-08
dc.description.abstract Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents. en_ZA
dc.description.department Immunology en_ZA
dc.description.embargo 2021-08-20
dc.description.librarian hj2020 en_ZA
dc.description.sponsorship The Cancer Association of South Africa (CANSA), the National Research Foundation (NRF) of South Africa and the NIH/NCI (Cancer Center Support Grant P30 CA008748). en_ZA
dc.description.uri http://link.springer.com/journal/520 en_ZA
dc.identifier.citation Suarez-Almazor, M.E., Pundole, X., Abdel-Wahab, N. et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Support Care in Cancer (2020). https://doi.org/10.1007/s00520-020-05710-8. en_ZA
dc.identifier.issn 0941-4355 (print)
dc.identifier.issn 1433-7339 (online)
dc.identifier.other 10.1007/s00520-020-05710-8
dc.identifier.uri http://hdl.handle.net/2263/76607
dc.language.iso en en_ZA
dc.publisher Springer en_ZA
dc.rights © Springer-Verlag GmbH Germany, part of Springer Nature 2020. The original publication is available at : http://link.springer.com/journal/520. en_ZA
dc.subject Arthralgia en_ZA
dc.subject Immune checkpoint inhibitor (ICI) en_ZA
dc.subject Arthritis en_ZA
dc.subject Cardiomyopathy en_ZA
dc.subject Corticosteroids en_ZA
dc.subject Myocarditis en_ZA
dc.subject Myositis en_ZA
dc.subject Immunomodulation agents en_ZA
dc.subject Other immunosuppressive agents en_ZA
dc.subject Polymyalgia en_ZA
dc.title Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors en_ZA
dc.type Postprint Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record